Document Detail


In vitro production of interleukin-1 receptor antagonist in chronic renal failure, CAPD and HD.
MedLine Citation:
PMID:  1474775     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Dialysis-related symptoms are believed to be mediated, at least in part, by monocyte/macrophage-derived pro-inflammatory cytokines including interleukin-1 (IL-1) and tumor necrosis factor (TNF). Measuring the production of interleukin-1 receptor antagonist (IL-Ra), a naturally occurring inhibitor of IL-1, opens avenues to study the balance between these two cytokines in patients. We studied the cell content and production of IL-1 beta and IL-Ra by unstimulated and endotoxin- or IgG-stimulated peripheral blood mononuclear cells (PBMC) in undialyzed patients with chronic renal failure (CRF), patients on continuous ambulatory peritoneal dialysis (CAPD) and patients on chronic hemodialysis with reuse cuprophan membranes (HD), and compared them to healthy controls. IL-1 beta and IL-Ra were measured by specific radioimmunoassay. IL-1 beta was undetectable in freshly harvested PBMC from healthy controls, CRF, CAPD or HD. In contrast, the content of IL-Ra in HD patients (2828 +/- 466 pg/ml) was significantly higher than that in healthy controls (643 +/- 53 pg/ml, P < 0.01), CRF (1097 +/- 320 pg/ml, P < 0.01) or CAPD (1398 +/- 390 pg/ml, P < 0.05). In endotoxin-stimulated PBMC, IL-1 beta production by HD patients (9375 +/- 1687 pg/ml) was not significantly different from healthy controls (8429 +/- 1621 pg/ml). However, endotoxin-stimulated IL-Ra production by HD patients (32,350 +/- 8276 pg/ml) was greater than that from healthy controls (11,284 +/- 1250 pg/ml, P < 0.001), CRF (12,263 +/- 2680 pg/ml, P < 0.01) or CAPD patients (11,822 +/- 1797 pg/ml, P < 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)
Authors:
B J Pereira; D D Poutsiaka; A J King; J A Strom; G Narayan; A S Levey; C A Dinarello
Related Documents :
21435025 - Thyroid autoimmunity associated with recurrent aphthous stomatitis.
19404765 - Loss via peritoneal fluid as a factor for low 25(oh)d3 level in peritoneal dialysis pat...
8175195 - The contribution of hemofiltration among the treatment modalities of chronic uremia.
20587875 - Beta-2 microglobulin levels in hemodialysis patients.
22185985 - Determinants of serum high molecular weight (hmw) adiponectin levels in patients with c...
15922265 - Scar-related right atrial macroreentrant tachycardia in patients without prior atrial s...
Publication Detail:
Type:  In Vitro; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Kidney international     Volume:  42     ISSN:  0085-2538     ISO Abbreviation:  Kidney Int.     Publication Date:  1992 Dec 
Date Detail:
Created Date:  1993-02-01     Completed Date:  1993-02-01     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0323470     Medline TA:  Kidney Int     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1419-24     Citation Subset:  IM    
Affiliation:
Department of Medicine, New England Medical Center Hospitals, Boston, Massachusetts.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Endotoxins / toxicity
Humans
Immunoglobulin G / administration & dosage
Interleukin 1 Receptor Antagonist Protein
Interleukin-1 / blood
Kidney Failure, Chronic / blood,  immunology*,  therapy
Leukocytes, Mononuclear / immunology,  metabolism
Middle Aged
Peritoneal Dialysis, Continuous Ambulatory / adverse effects
Receptors, Interleukin-1 / antagonists & inhibitors*
Renal Dialysis / adverse effects
Sialoglycoproteins / biosynthesis*,  blood
Grant Support
ID/Acronym/Agency:
AI 15614/AI/NIAID NIH HHS
Chemical
Reg. No./Substance:
0/Endotoxins; 0/IL1RN protein, human; 0/Immunoglobulin G; 0/Interleukin 1 Receptor Antagonist Protein; 0/Interleukin-1; 0/Receptors, Interleukin-1; 0/Sialoglycoproteins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Convection does not govern plasma to dialysate transport of protein.
Next Document:  Nature and rate of vascular refilling during hemodialysis and ultrafiltration.